Stock Trading Canary

United States · SEC Form 4 · Snapshot date: 2026-10-18 · Built: 2026-10-18 · 中文

← United States · Coverage record

US · SEC FORM 4

Intellia Therapeutics, Inc.

NTLA · Nasdaq · CIK 0001652130 · Healthcare · Biotechnology

INSIDER SIGNAL

No active buy signal

0 qualifying P purchase groups
in the current 180-day scoring window

13 Form 4 transaction lines observed in the same window
6 sales · 7 option, withholding, award, gift or other lines

Last qualifying purchase2026-01-05 · Cohen Fred E · $1.4M

WHY NO ACTIVE SIGNAL?

Purchase activityNone
Recent buyingNone
Recent salesModerate
Buy signal statusInactive
Score anatomy

No score is calculated because there is no qualifying purchase in the active window. Unavailable inputs are not treated as zero or as a bearish signal.

ClusterNot calculated
Purchase sizeNot calculated
RoleNot calculated
RecencyNot calculated
ConvictionNot calculated

Why is there no score?

  • No qualifying open-market purchase supplies cluster, size, role, recency or conviction inputs.
  • Sales and other Form 4 activity remain visible as context and do not create a negative score.

Sales and other Form 4 activity are shown separately and do not create a negative buy signal. Absence of buying is not scored as bearish.

Insider activity timeline

Owner lanes show the latest 180 days. Symbol shape identifies the transaction type; sales remain context only.

AprMayJunJulAugSepOct
LEONARD JOHN MPresident and CEO
▼▼
Dulac Edward J IIIEVP, Chief Financial Officer
▼▼
Dube Michael PVP, Chief Accounting Officer
▼▼
Verwiel FrankDirector
○
Keresty GeorgiaDirector
○
Goff BrianDirector
○
● Purchase▼ Sale○ Other

Showing the six most active owners; 4 additional owner(s) remain in Form 4 evidence.

Purchase breadth, concentration & cluster buying

These modules activate when qualifying purchases enter the 180-day research window.

SIGNAL HISTORY

No recorded active-signal snapshot

Scores are archived only when the company qualifies for a published US buy-signal snapshot. Last qualifying purchase: 2026-01-05 · Cohen Fred E.

Recent Form 4 activity

1Purchases
18Sales
16Other Form 4 lines
28SEC filings · 365 days
BUYING0 qualifying P line(s) · 180 days
SELLING6 sale line(s) · context only
OTHER7 exercise / withholding / award / gift / other lines
10b5-1 / PLANNEDNot assessed

P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.

Market context

Market context has not been captured for this ticker yet. The daily market-context job processes the US universe in rotating batches.

Short interest

Short interest is external context reported to FINRA by broker-dealers. It does not affect the Insider Signal.

Shares short
45,110,513
Previous report
46,681,609
Avg daily volume
4,765,594
Days to cover
9.5

FINRA settlement date: 2026-09-30 · Captured 2026-10-12 · FINRA equity short interest ↗. A share count, published about a week after each of two settlement dates a month; not a percentage of shares outstanding.

Historical equity purchases

Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.

Transaction dateReporting ownerTypeSecuritySharesAvg. priceApprox. valueSource
2026-01-05Cohen Fred EPurchase (P)Common Stock150,000USD 9.35USD 1,402,500SEC filing ↗
2025-08-20CHASE WILLIAM JPurchase (P)Common Stock100,000USD 10.03USD 1,003,000SEC filing ↗

Form 4 evidence

35 transaction lines in the latest 365-day window; 441 in local history.

DateOwnerTypeSecuritySharesAvg. priceApprox. valueSource
2026-10-02Dube Michael PSale (S)Common Stock1,864USD 12.43USD 23,170SEC filing ↗
2026-08-21LEONARD JOHN MSale (S)Common Stock2,785USD 13.00USD 36,205SEC filing ↗
2026-08-20LEONARD JOHN MSale (S)Common Stock19,890USD 12.60USD 250,614SEC filing ↗
Show recent Form 4 evidence (30 grouped rows)
DateOwnerTypeSecuritySharesAvg. priceApprox. valueSource
2026-10-02Dube Michael PSale (S)Common Stock1,864USD 12.43USD 23,170SEC filing ↗
2026-08-21LEONARD JOHN MSale (S)Common Stock2,785USD 13.00USD 36,205SEC filing ↗
2026-08-20LEONARD JOHN MSale (S)Common Stock19,890USD 12.60USD 250,614SEC filing ↗
2026-07-22Dulac Edward J IIISale (S)Common Stock8,111USD 11.25USD 91,249SEC filing ↗
2026-07-02Dulac Edward J IIISale (S)Common Stock4,677USD 18.00USD 84,186SEC filing ↗
2026-07-01Dube Michael PSale (S)Common Stock2,641USD 16.78USD 44,316SEC filing ↗
2026-06-09Verwiel FrankAward / grant (A)Common Stock9,200USD 0.00USD 0SEC filing ↗
2026-06-09Keresty GeorgiaAward / grant (A)Common Stock9,200USD 0.00USD 0SEC filing ↗
2026-06-09Goff BrianAward / grant (A)Common Stock9,200USD 0.00USD 0SEC filing ↗
2026-06-09GOODMAN JESSEAward / grant (A)Common Stock9,200USD 0.00USD 0SEC filing ↗
2026-06-09Cohen Fred EAward / grant (A)Common Stock9,200USD 0.00USD 0SEC filing ↗
2026-06-09CHASE WILLIAM JAward / grant (A)Common Stock9,200USD 0.00USD 0SEC filing ↗
2026-06-09Bhanji MunaAward / grant (A)Common Stock9,200USD 0.00USD 0SEC filing ↗
2026-03-02Clark ElianaSale (S)Common Stock607USD 13.78USD 8,364SEC filing ↗
2026-03-02BASTA JAMESSale (S)Common Stock1,211USD 13.78USD 16,688SEC filing ↗
2026-03-01Schultes Birgit CAward / grant (A)Common Stock39,200USD 0.00USD 0SEC filing ↗
2026-03-01Lebwohl DavidAward / grant (A)Common Stock9,943USD 0.00USD 0SEC filing ↗
2026-03-01LEONARD JOHN MAward / grant (A)Common Stock156,400USD 0.00USD 0SEC filing ↗
2026-03-01Dulac Edward J IIIAward / grant (A)Common Stock61,280USD 0.00USD 0SEC filing ↗
2026-03-01Dube Michael PAward / grant (A)Common Stock17,250USD 0.00USD 0SEC filing ↗
2026-03-01Clark ElianaAward / grant (A)Common Stock7,353USD 0.00USD 0SEC filing ↗
2026-03-01BASTA JAMESAward / grant (A)Common Stock46,080USD 0.00USD 0SEC filing ↗
2026-01-05Schultes Birgit CSale (S)Common Stock8,508USD 9.21USD 78,359SEC filing ↗
2026-01-05Lebwohl DavidSale (S)Common Stock11,903USD 9.21USD 109,627SEC filing ↗
2026-01-05LEONARD JOHN MSale (S)Common Stock34,146USD 9.21USD 314,485SEC filing ↗
2026-01-05Dulac Edward J IIISale (S)Common Stock6,379USD 9.21USD 58,751SEC filing ↗
2026-01-05Dube Michael PSale (S)Common Stock2,989USD 9.21USD 27,529SEC filing ↗
2026-01-05Cohen Fred EPurchase (P)Common Stock150,000USD 9.35USD 1,402,500SEC filing ↗
2026-01-05Clark ElianaSale (S)Common Stock9,515USD 9.21USD 87,633SEC filing ↗
2026-01-05BASTA JAMESSale (S)Common Stock10,397USD 9.21USD 95,756SEC filing ↗

Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.

Snapshot & identity

Snapshot date2026-10-18
Ranking versionUS-v1.2
Data qualityPASS ELIGIBLE · —
TickerNTLA
CIK0001652130
SectorHealthcare
IndustryBiotechnology Yahoo Finance
SEC SIC2835 In Vitro & In Vivo Diagnostic Substances
ExchangeNasdaq

Data coverage

Local Form 4 history441 transaction lines from 2020-05-26 to 2026-10-02
2 P purchase lines · 260 S sale lines · 179 other lines
SEC company submissionsOpen SEC filings ↗

Local ledger as of 2026-10-18. Mapping status is an audit field and does not erase SEC filing evidence.